新日恆力(600165.SH):5萬噸/年月桂二酸項目結束試生產 已小批量進入市場銷售
格隆匯9月6日丨新日恆力(600165.SH)公佈,公司5萬噸/年月桂二酸項目(以下簡稱:月桂二酸項目)已於2021年9月3日結束試生產,試生產產品指標達到聚合級要求,已小批量進入市場銷售。
根據公司與中國科學院微生物研究所簽訂的《技術轉讓合同》中約定的規模化生產標準:“以連續3天運行6批次的平均產量,推算出月產量、年產量和總體產能。能夠達到設計產能的80%視為達到規模化生產的要求”。月桂二酸項目將於2021年10月起正式投產,待產量達到上述約定標準後,公司將組織驗收,驗收合格前,月桂二酸項目仍列入在建工程科目核算。
月桂二酸項目符合國家產業政策及公司發展戰略,月桂二酸項目的投產有利於公司進一步擴大生產經營規模,增加產品種類和優化產品結構,有利於提升公司綜合競爭力,對公司長期經營發展起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.